Why generative AI matters in pharmacovigilance
Pharmacovigilance teams must turn fragmented information into accurate, traceable safety decisions. Reports arrive through spontaneous cases, clinical trials, medical information centres, literature, patient-support programmes, call recordings, and digital channels. Much of the input is unstructured, multilingual, incomplete, or duplicated.
Generative AI for drug safety monitoring and reporting can reduce the manual effort involved in reading, extracting, coding, summarising, and drafting. It should not be treated as an autonomous medical decision-maker. The strongest 2026 implementations use AI as a controlled workflow layer around validated safety systems, with qualified reviewers accountable for every report submitted or retained.
For Indian pharmaceutical companies and CROs, the business case is particularly strong: global case volumes are rising, teams support multiple markets, and local operations must maintain consistency while working with English, Hindi, and other Indian-language inputs.
High-value use cases
1. Case intake and triage
An AI intake service can classify incoming text and attachments, identify potential individual case safety reports (ICSRs), and route them to the correct queue. It can extract:
- Suspect and concomitant products, including brand and generic names
- Patient characteristics, dates, dose, route, indication, and treatment duration
- Adverse events, outcomes, seriousness, and reporter details
- Dechallenge, rechallenge, medical history, and relevant laboratory findings
- Missing information needed for follow-up
The model should return each extracted field with its source passage, confidence score, and document location. This makes reviewer verification faster and creates evidence for an audit trail. Multilingual processing can support initial translation, but clinical reviewers must verify terminology, negation, and culturally specific expressions before final coding.
2. MedDRA coding and structured data creation
Generative models can suggest MedDRA Lowest Level Terms and Preferred Terms from colloquial descriptions, while rules and deterministic checks protect against unsafe substitutions. For example, “felt breathless after the tablet” may require more context than a direct keyword match. The system should show alternative terms, explain the recommendation, and preserve the original reporter wording.
Do not allow a language model to silently overwrite coded data. Maintain the source text, selected term, dictionary version, coder identity, model version, and approval timestamp. Dictionary updates also require regression testing because the same input can produce different results after a MedDRA release or prompt change.
3. Narrative drafting and case summarisation
AI can assemble a chronology from source documents and draft a concise case narrative in the organisation’s approved format. It can highlight contradictions—such as conflicting onset dates—or identify facts that are absent rather than filling gaps creatively.
A production prompt should instruct the model to use only supplied evidence, distinguish reported facts from interpretation, preserve uncertainty, and mark missing values explicitly. Safety physicians remain responsible for medical assessment, seriousness, expectedness, causality, and the final narrative.
4. Literature and media monitoring
Monitoring teams can use AI to screen publications, abstracts, regulatory updates, and relevant online content. A retrieval-based workflow can extract product mentions, safety outcomes, study design, and reportability indicators, then send potential cases for review. This is an effective extension of how to automate media monitoring with AI, provided source documents and search decisions remain reproducible.
Summaries are not evidence by themselves. Store the original article, retrieval query, screening result, and reviewer disposition. That record is essential when demonstrating why a source was included or excluded.
5. Signal detection support
Generative AI is most useful when it adds context to statistical and rule-based signal detection. It can group related concepts, compare emerging patterns across products or geographies, summarise case series, and prepare questions for a signal review meeting. It should not replace disproportionality analysis, epidemiological assessment, or expert judgement.
A safe design separates candidate generation from signal confirmation. The first stage may favour recall; the second requires reproducible evidence, defined thresholds, documented alternatives, and medical review.
Designing a compliant AI workflow
A practical architecture usually includes an ingestion layer, document and identity controls, extraction models, a validated safety database, reviewer work queues, and immutable audit logging. For complex workflows, teams can use narrowly scoped generative AI agents, but each agent should have limited permissions and a clear hand-off to a human reviewer.
Use retrieval-augmented generation rather than relying on a model’s general memory. Connect the model to approved SOPs, current coding dictionaries, product information, and controlled templates. Apply deterministic validation for dates, mandatory fields, duplicate identifiers, seriousness criteria, and submission formats.
A minimum control set includes:
- Role-based access and least-privilege permissions
- Encryption in transit and at rest
- Redaction or tokenisation of unnecessary personal data
- Tenant isolation when using a shared cloud service
- Prompt, model, source-document, and output versioning
- Human approval before regulatory transmission
- Monitoring for hallucination, omission, bias, drift, and latency
- A documented rollback and incident-response process
India-focused deployments should assess obligations under the Digital Personal Data Protection Act, contractual data-transfer requirements, applicable CDSCO and PvPI expectations, and the rules of every market receiving the output. Regulatory acceptance depends less on the word “AI” than on demonstrable control, validation, data integrity, and accountability.
Validation and performance metrics
Do not validate a pharmacovigilance model only on average accuracy. Build a representative, de-identified test set covering serious cases, rare events, negation, abbreviations, poor scans, duplicate reports, multilingual text, and incomplete narratives. Have independent safety professionals establish the reference standard.
Track metrics by task and risk level:
- Case identification sensitivity and false-negative rate
- Field-level extraction precision and recall
- MedDRA agreement with expert coders
- Duplicate-detection precision and review burden
- Narrative factuality, omission rate, and edit distance
- Time saved per case without reducing quality
- Reviewer overrides and reasons for correction
- Performance across languages, source types, products, and sites
Continuous LLM application performance monitoring should cover both technical health and clinical safety. A model that is fast but misses serious cases is not successful. Establish release gates, periodic revalidation, and a process for investigating unexpected outputs.
A sensible implementation roadmap
Start with a narrow, measurable workflow such as literature triage, document classification, or draft extraction for non-critical fields. Map the current process, identify failure points, and define who approves each transition. Run the AI in shadow mode against existing work before allowing it to influence production queues.
Next, integrate reviewer feedback and expand to narrative drafting or coding suggestions. Keep automated actions reversible. Only after evidence supports the use case should the system receive limited production permissions. Procurement teams should ask vendors about training-data use, data retention, residency, model updates, audit exports, API security, and business continuity.
For enterprise teams, generative AI productivity tools for enterprise India offer useful lessons on governance, adoption, and change management—but pharmacovigilance requires stricter validation and medical accountability.
What the future looks like
The next phase will connect safety data with real-world evidence, electronic health records, patient-support programmes, and device data. These sources may improve earlier detection, but they also introduce consent, representativeness, interoperability, and false-positive risks. Indian builders should prioritise explainable workflows, vernacular language support, secure deployment, and integration with existing safety databases rather than building another unconnected chatbot.
Generative AI can make pharmacovigilance faster and more consistent. Its value is realised when every acceleration is matched by stronger provenance, review, and controls.
Frequently asked questions
Can generative AI replace pharmacovigilance specialists?
No. It can automate repetitive reading and drafting, while medical experts retain responsibility for assessment, review, and reporting decisions.
Can it process Indian-language adverse-event reports?
Yes, but translation and extraction must be validated for clinical meaning, negation, dosage, and local expressions. Keep the original text for review.
Should AI submit cases directly to regulators?
Not by default. Use human approval, deterministic format checks, complete audit logs, and a validated interface before any transmission.
Support for Indian AI builders
Teams developing privacy-preserving pharmacovigilance systems can explore support through AI Grants India. A strong application should define the safety problem, target users, validation dataset, regulatory pathway, measurable outcomes, and safeguards—not just the underlying model.